| . | All patients (n= 519) . | Patients not returning for follow-up (n= 207) . | Patients returning for follow-up (n= 312) . | P value . |
|---|---|---|---|---|
| Gender, female [n (%)] | 315 (60.7) | 121 (58.4) | 194 (62.2) | 0.395 |
| Age [mean (SD)] | 35.7 (24.2) | 31.4 (22.5) | 38.5 (24.9) | 0.001 |
| Caucasian [n (%)] | 478/504 (94.8) | 188/203 (92.6) | 290/301 (96.4) | 0.063 |
| Patient reported allergic history [n (%)] | 345 (66.5) | 136 (65.7) | 209 (67.0) | 0.761 |
| Smoking status [n (%)] | 0.414 | |||
| Never | 359 (69.2) | 149 (72.0) | 210 (67.3 | |
| Former | 105 (20.2) | 36 (17.4) | 69 (22.1) | |
| Current | 55 (10.6) | 22 (10.6) | 33 (10.6) | |
| FEV1 as % predicted [mean (SD)] | 94.6 (20.4) | 97.1 (19.5) | 92.9 (20.8) | 0.029 |
| Patient taking any controller medication [n (%)] | 433 (83.4) | 165 (79.7) | 268 (85.9) | 0.063 |
| ICS alone [n (%)] | 132 (25.4) | 62 (30.0) | 70 (22.4) | 0.054 |
| LTRA alone [n (%)] | 17 (3.3) | 7 (3.4) | 10 (3.2) | 0.912 |
| Combination therapy (ICS + LABA) [n (%)] | 270 (52.0) | 94 (45.4) | 176 (56.4) | 0.014 |
| Rescue medication in doses/day [mean (SD)] | 0.597 (1.233) | 0.524 (1.113) | 0.646 (1.306) | 0.271 |
| . | All patients (n= 519) . | Patients not returning for follow-up (n= 207) . | Patients returning for follow-up (n= 312) . | P value . |
|---|---|---|---|---|
| Gender, female [n (%)] | 315 (60.7) | 121 (58.4) | 194 (62.2) | 0.395 |
| Age [mean (SD)] | 35.7 (24.2) | 31.4 (22.5) | 38.5 (24.9) | 0.001 |
| Caucasian [n (%)] | 478/504 (94.8) | 188/203 (92.6) | 290/301 (96.4) | 0.063 |
| Patient reported allergic history [n (%)] | 345 (66.5) | 136 (65.7) | 209 (67.0) | 0.761 |
| Smoking status [n (%)] | 0.414 | |||
| Never | 359 (69.2) | 149 (72.0) | 210 (67.3 | |
| Former | 105 (20.2) | 36 (17.4) | 69 (22.1) | |
| Current | 55 (10.6) | 22 (10.6) | 33 (10.6) | |
| FEV1 as % predicted [mean (SD)] | 94.6 (20.4) | 97.1 (19.5) | 92.9 (20.8) | 0.029 |
| Patient taking any controller medication [n (%)] | 433 (83.4) | 165 (79.7) | 268 (85.9) | 0.063 |
| ICS alone [n (%)] | 132 (25.4) | 62 (30.0) | 70 (22.4) | 0.054 |
| LTRA alone [n (%)] | 17 (3.3) | 7 (3.4) | 10 (3.2) | 0.912 |
| Combination therapy (ICS + LABA) [n (%)] | 270 (52.0) | 94 (45.4) | 176 (56.4) | 0.014 |
| Rescue medication in doses/day [mean (SD)] | 0.597 (1.233) | 0.524 (1.113) | 0.646 (1.306) | 0.271 |
SD, standard deviation; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; LABA, long-acting B-agonist; FEV1, forced expiratory volume in 1 s.
| . | All patients (n= 519) . | Patients not returning for follow-up (n= 207) . | Patients returning for follow-up (n= 312) . | P value . |
|---|---|---|---|---|
| Gender, female [n (%)] | 315 (60.7) | 121 (58.4) | 194 (62.2) | 0.395 |
| Age [mean (SD)] | 35.7 (24.2) | 31.4 (22.5) | 38.5 (24.9) | 0.001 |
| Caucasian [n (%)] | 478/504 (94.8) | 188/203 (92.6) | 290/301 (96.4) | 0.063 |
| Patient reported allergic history [n (%)] | 345 (66.5) | 136 (65.7) | 209 (67.0) | 0.761 |
| Smoking status [n (%)] | 0.414 | |||
| Never | 359 (69.2) | 149 (72.0) | 210 (67.3 | |
| Former | 105 (20.2) | 36 (17.4) | 69 (22.1) | |
| Current | 55 (10.6) | 22 (10.6) | 33 (10.6) | |
| FEV1 as % predicted [mean (SD)] | 94.6 (20.4) | 97.1 (19.5) | 92.9 (20.8) | 0.029 |
| Patient taking any controller medication [n (%)] | 433 (83.4) | 165 (79.7) | 268 (85.9) | 0.063 |
| ICS alone [n (%)] | 132 (25.4) | 62 (30.0) | 70 (22.4) | 0.054 |
| LTRA alone [n (%)] | 17 (3.3) | 7 (3.4) | 10 (3.2) | 0.912 |
| Combination therapy (ICS + LABA) [n (%)] | 270 (52.0) | 94 (45.4) | 176 (56.4) | 0.014 |
| Rescue medication in doses/day [mean (SD)] | 0.597 (1.233) | 0.524 (1.113) | 0.646 (1.306) | 0.271 |
| . | All patients (n= 519) . | Patients not returning for follow-up (n= 207) . | Patients returning for follow-up (n= 312) . | P value . |
|---|---|---|---|---|
| Gender, female [n (%)] | 315 (60.7) | 121 (58.4) | 194 (62.2) | 0.395 |
| Age [mean (SD)] | 35.7 (24.2) | 31.4 (22.5) | 38.5 (24.9) | 0.001 |
| Caucasian [n (%)] | 478/504 (94.8) | 188/203 (92.6) | 290/301 (96.4) | 0.063 |
| Patient reported allergic history [n (%)] | 345 (66.5) | 136 (65.7) | 209 (67.0) | 0.761 |
| Smoking status [n (%)] | 0.414 | |||
| Never | 359 (69.2) | 149 (72.0) | 210 (67.3 | |
| Former | 105 (20.2) | 36 (17.4) | 69 (22.1) | |
| Current | 55 (10.6) | 22 (10.6) | 33 (10.6) | |
| FEV1 as % predicted [mean (SD)] | 94.6 (20.4) | 97.1 (19.5) | 92.9 (20.8) | 0.029 |
| Patient taking any controller medication [n (%)] | 433 (83.4) | 165 (79.7) | 268 (85.9) | 0.063 |
| ICS alone [n (%)] | 132 (25.4) | 62 (30.0) | 70 (22.4) | 0.054 |
| LTRA alone [n (%)] | 17 (3.3) | 7 (3.4) | 10 (3.2) | 0.912 |
| Combination therapy (ICS + LABA) [n (%)] | 270 (52.0) | 94 (45.4) | 176 (56.4) | 0.014 |
| Rescue medication in doses/day [mean (SD)] | 0.597 (1.233) | 0.524 (1.113) | 0.646 (1.306) | 0.271 |
SD, standard deviation; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; LABA, long-acting B-agonist; FEV1, forced expiratory volume in 1 s.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
